00:03 , May 19, 2018 |  BioCentury  |  Politics, Policy & Law

Shifting parts

HHS Secretary Alex Azar is convinced that the way Medicare Part B spends money for drugs makes no sense, costs the taxpayers too much and isn’t good for patients. He says he’s open to suggestions...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Financial News

Access Bio completes private placement of convertible notes

Access Bio Inc. (KOSDAQ:950130), Somerset, N.J.   Business: Diagnostic   Date completed: 2016-03-30   Type: Private placement of convertible notes   Raised: $8 million   Shares outstanding prior: 26.8 million   Investor: Global Health Investment Fund   Note: The company declined to...
07:00 , Sep 16, 2002 |  BioCentury  |  Regulation

Avoiding collateral damage

A week after Acting FDA Commissioner Lester Crawford announced that review of most therapeutic biologics will move from the Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research, some information...